What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France.
Alzheimer’s disease
biomarkers
cerebrospinal fluid
clinical practice
mild cognitive impairment
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
30 05 2019
30 05 2019
Historique:
entrez:
2
6
2019
pubmed:
4
6
2019
medline:
5
6
2020
Statut:
epublish
Résumé
New diagnostic criteria for Alzheimer's disease (AD) include cerebrospinal fluid (CSF) biomarkers that allow diagnosis at the stage of mild cognitive impairment (MCI). However, the impact of CSF biomarkers in MCI populations in clinical practice has been poorly evaluated. The objective of this study is to assess the use and impact in clinical practice of AD CSF biomarkers in French memory clinics. We performed a nation-wide, prospective survey between March 2012 and September 2014. Data over the same period was extracted from the French National Database (Banque Nationale Alzheimer, BNA) and compared with the results of the survey. 29 secondary and tertiary memory clinics in France. Clinicians prescribing lumbar puncture (LP) in order to measure AD CSF biomarkers. Clinicians completed a two-part questionnaire for each of their patients undergoing LP. Assessment of diagnosis, level of confidence before and after CSF biomarkers and impact on management in patients who underwent LP for CSF AD biomarkers in clinical routine. 977 questionnaires were completed, of which 61 were excluded because of unknown initial/final diagnosis or non-contributory CSF results. Of 916 patients reported, 153 (16.7%) had MCI as the initial diagnosis, of which 51 (33.3%) displayed an AD profile. CSF biomarkers resulted in a change in diagnosis in 44 patients (28.8%). Confidence level significantly increased after LP (8.3±1.4vs 6.73±1.18, p<0.0001), and CSF results modified management in 71/156 patients (46.4%), including 36 (23.5%) enrolled in clinical trials. Comparison of change in diagnosis with the BNA population revealed no difference (32.24%, p=0.4). This nation-wide survey, reflecting clinical practice in French memory clinics, describes the impact of CSF AD biomarkers in patients with MCI in clinical practice.
Identifiants
pubmed: 31152032
pii: bmjopen-2018-026380
doi: 10.1136/bmjopen-2018-026380
pmc: PMC6549619
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e026380Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Neurol. 2014 Jan;261(1):144-51
pubmed: 24162039
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
Pharmacoecon Open. 2018 Sep;2(3):309-323
pubmed: 29623628
JAMA Neurol. 2017 Dec 1;74(12):1481-1491
pubmed: 29049480
J Alzheimers Dis. 2018;61(1):373-388
pubmed: 29154285
Brain. 2015 May;138(Pt 5):1327-38
pubmed: 25693589
Neurology. 2016 Sep 20;87(12):1235-41
pubmed: 27558378
J Alzheimers Dis. 2017;60(4):1477-1487
pubmed: 29081416
Alzheimers Dement. 2015 Jan;11(1):58-69
pubmed: 24795085
Alzheimers Res Ther. 2016 Dec 9;8(1):51
pubmed: 27931251
Dement Geriatr Cogn Disord. 2014;38(5-6):271-80
pubmed: 24994018
Lancet Neurol. 2006 Mar;5(3):228-34
pubmed: 16488378
Dement Geriatr Cogn Disord. 2010;29(6):491-7
pubmed: 20523047
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Alzheimers Dement. 2015 Aug;11(8):896-905
pubmed: 26071009
Arch Neurol. 2009 Mar;66(3):382-9
pubmed: 19273758
J Alzheimers Dis. 2014;40(4):857-61
pubmed: 24577469
Neurology. 2012 Jan 3;78(1):47-54
pubmed: 22170879